
News|Articles|November 24, 2025
De-Risking Clinical Development: Strategic Multipliers in Global Trials
Author(s)Seriant
Key Takeaways
- Personalized treatment strategies have advanced the management of lung cancer brain metastases, integrating targeted therapies and immunotherapies for improved patient outcomes.
- Stereotactic radiosurgery and whole-brain radiation therapy are evolving with novel systemic therapies, maintaining their importance in treatment plans.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
Novo Nordisk’s Stock Reacts to Unsuccessful Phase III Trial Results
2
What Does the List of Approved Drugs Reveal About FDA's Priority Review Voucher Program?
3
Winning the Next Era of Direct-to-Patient Drug Distribution: Why End-to-End Integration Matters More Than Assembly
4
What Successes and Setbacks Occurred in Neurosciences in 2025?
5
